A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy

Pfizer87 enrolled

Overview

The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the treatment of advanced stage non-small cell lung cancer.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lung Neoplasms

Interventions

CP-547,632DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically or cytologically confirmed stage IIIB (inicluding those with pleural effusion), IV or recurrent non-small cell lung cancer (nsclc). * Bidimensionally measurable disease \>2cm x 1 cm by conventional CT Scan or \>1 cm x 1cm by spiral CT Scan. Exclusion Criteria: * No tumors in close proximity to major veins or arteries. * No sanguinous pleural effusion due to disease or pericardial effusion suspicious for disease. * No evidence or history brain metastases.

Locations (20)

Pfizer Investigational Site

Greenbrae, California, United States

Pfizer Investigational Site

Outcomes

Primary Outcomes

Statistical estimates used on the Stage 1 data indicated low likely-hood of a positive outcome if the study continued to Stage 2. This provided the basis for discontinuation of the trial.

Secondary Outcomes

Given the outcome of the primary objective, analysis of secondary objectives were not formalized.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.